Harry H. Yoon

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · Journal of the National Comprehensive Cancer Network · 2022 · 1.7K citations · Full text

Medicine, Molecular Medicine, Oncology +17

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · Journal of the National Comprehensive Cancer Network · 2023 · 520 citations · Full text

Medicine, Oncology, Pathology +17

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Joseph Chao, Charles S. Fuchs, Kohei Shitara et al. · JAMA Oncology · 2021 · 443 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +12

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

Jianming Xu, Ken Kato, Eric Raymond et al. · The Lancet Oncology · 2023 · 291 citations

Medicine, Oncology, Pharmacology +12

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Yung‐Jue Bang, Yoon‐Koo Kang, Daniel V.T. Catenacci et al. · Gastric Cancer · 2019 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17